Daniel Snell

Title: The Innovative Contributions of Daniel Snell

Introduction

Daniel Snell is a notable inventor based in Thalwil, Switzerland. He has made significant contributions to the field of immunology through his innovative patents. With a total of three patents to his name, Snell's work focuses on humanized monoclonal antibodies and their applications in immunosuppressive therapy.

Latest Patents

One of Snell's latest patents is related to an anti-αβTCR antibody. This invention involves humanized monoclonal antibodies that comprise the CDRs of murine antibody BMA031. These antibodies bind to the apTCR.CD3 complex and possess improved biological properties. Another significant patent details methods for enhancing immunosuppressive therapy through the multiple administration of αβTCR-binding polypeptides. This disclosure focuses on improved methods for using a humanized binding polypeptide specific for the alpha beta T cell receptor. Additionally, Snell has developed novel methods using repetitive administration of humanized monoclonal antibodies to reduce αβ T cells in subjects relative to γδ cells.

Career Highlights

Throughout his career, Daniel Snell has worked with prominent organizations such as Genzyme Corporation and Eberhard Karls Universität Tübingen. His experience in these institutions has contributed to his expertise in the field of immunology and antibody development.

Collaborations

Snell has collaborated with notable colleagues, including Andreas Menrad and Gina Lacorcia. These partnerships have likely enhanced his research and development efforts in the field.

Conclusion

Daniel Snell's innovative work in the development of humanized monoclonal antibodies has the potential to significantly impact immunosuppressive therapies. His contributions to the field are marked by his patents and collaborations, showcasing his dedication to advancing medical science.